Biotransformation of Post-Clozapine Antipsychotics

@article{Caccia2000BiotransformationOP,
  title={Biotransformation of Post-Clozapine Antipsychotics},
  author={Silvio Caccia},
  journal={Clinical Pharmacokinetics},
  year={2000},
  volume={38},
  pages={393-414}
}
  • S. Caccia
  • Published 1 May 2000
  • Medicine
  • Clinical Pharmacokinetics
The need to develop new antipsychotics that have fewer motor adverse effects and offer better treatment of negative symptoms has led to a new generation of drugs. Most of these drugs undergo extensive first-pass metabolism and are cleared almost exclusively by metabolism, except for amisulpride whose clearance is largely due to urinary excretion.Risperidone has metabolic routes in common with ziprasidone but shows differences in regard to other main pathways: the benzisoxazole moiety of… Expand
Cytochrome P450 polymorphisms and response to antipsychotic therapy.
TLDR
YP2D6 phenotyping and genotyping appear, therefore, to be clinically useful for dose predicting only in special cases and for a limited number of antipsychotics, while their usefulness in predicting clinical effects must be further explored. Expand
Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
TLDR
Optimal plasma concentration ranges are proposed for clozapine, risperidone, paliperidone and olanzapine because the studies of quetiapine and amisulpride provide only limited information and there is no direct evidence concerning ziprasid one, aripiprazole, sertindole, brexpiprazoles and cariprazine. Expand
Clinical Pharmacokinetics of Atypical Antipsychotics
TLDR
This review of the literature concerning the relationships between plasma concentrations of SGAs and clinical responses is divided by dividing the studies on the basis of the length of their observation periods by indicating a relationship between clinical outcomes and plasma concentrations. Expand
Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics
  • M. Dahl
  • Biology, Medicine
  • Clinical pharmacokinetics
  • 2002
TLDR
The current rapid developments in molecular genetic methodology and pharmacogenetic knowledge can in the near future be expected to provide new tools for prediction of the activity of the various drugmetabolising enzymes. Expand
Fatalities Associated with Therapeutic Use and Overdose of Atypical Antipsychotics
Since 1989, several novel antipsychotic drugs have become available for use including clozapine, risperidone, olanzapine, quetiapine and ziprasidone. These agents represent a substantial improvementExpand
Relationship between P-glycoprotein and second-generation antipsychotics.
TLDR
An internet search for all relevant English original research articles concerning P-gp and second-generation antipsychotics (SGAs) found some variability in the findings concerning adverse effects, and no definitive conclusions can be drawn. Expand
Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?
TLDR
In order to introduce iloperidone as an agent for the treatment of schizophrenia, a short overview of the disease and of the most important antipsychotic drugs available or under development will be reported. Expand
Metabolism of Psychotropic Drugs
TLDR
In this chapter, specific metabolism of antidepressant and antipsychotic drugs is presented for the main CYP enzymes CYP2D6, CyP2C19, CYP 2C9, and CYP1A2 and the impact of genetic polymorphisms in these enzymes is pointed out. Expand
Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.
TLDR
It is indicated that mirtazapine has a negligible effect on the metabolism of clozapine, risperidone and olanzapine and can be added safely to an existing treatment with these antipsychotics. Expand
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.
TLDR
The results suggest that P-gp is likely to influence the access to the brain of all of the atypical antipsychotics studied to various degrees, and in vivo studies are needed to confirm these findings. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 169 REFERENCES
Drug metabolism and atypical antipsychotics
TLDR
There is, however, a general paucity of in vivo data regarding the metabolism of the atypical antipsychotics, indicating a need for further research in this area. Expand
The emerging role of cytochrome P450 3A in psychopharmacology.
TLDR
Knowing the substrates, inhibitors, and inducers of CYP3A3/ and other cytochrome P450 isoforms may help clinicians to anticipate and avoid pharmacokinetic drug interactions and improve rational prescribing practices. Expand
Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4
TLDR
The formation of 9-Hydroxyrisperidone is highly correlated with testosterone 6β-hydroxylase activities, suggesting that inducible CYP3A contributes significantly to the metabolism of ris peridone in rat. Expand
Metabolism of the Newer Antidepressants
  • S. Caccia
  • Medicine
  • Clinical pharmacokinetics
  • 1998
TLDR
Several chemically unrelated agents has been developed and introduced in the past decade, to supplement the earlier antidepressants, as well as drugs with distinct neurochemical profiles such as mirtazapine, nefazodone, moclobemide and tianeptine, which may explain the individual variability with all these drugs. Expand
The Metabolism of Atypical Antipsychotic Drugs: An Update
  • W. Shen
  • Psychology, Medicine
  • Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 1999
TLDR
None of all six atypical antipsychotic drugs are identified as significant inhibitors or inducers to any co-administered medication, and the need for more research to address some pertinent clinical issues in the metabolism of those drugs is suggested. Expand
Polymorphic Drug Oxidation
TLDR
The high incidence of PM (and of heterozygous extensive metabolisers) of S-mephenytoin in Asia might be the reason for the reported higher sensitivity of Orientals to diazepam compared with Caucasians. Expand
A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5‐HT2 and dopamine D2 receptors
TLDR
The clinical success of risperidone suggests that the development of compounds with selective affinity for 5-HT2 or other serotonin receptors may result in even further improvements in the pharmacotherapy of psychiatric disorders. Expand
In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A.
TLDR
In all cases, the calculated percent inhibition of these cytochromes P450 by olanzapine was < 0.3%, suggesting that there would be little in vivo inhibition of the metabolism of substrates of these enzymes when co-administered with olanZapine. Expand
New antipsychotics: the present status
TLDR
According to this classification the new antipsychotics can be subdivided into three main categories: the relatively pure dopamine antagonists; the dopamine (D2)-serotonin (5-HT2)-norepinephrine (α1 ) antagonists (risperidone, ziprazidone and sertindole); and the multireceptor antagonists (clozapine, olanzapine and seroquel). Expand
Pharmacokinetics and drug interactions: update for new antipsychotics.
TLDR
Clozapine, the archetypal atypical agent, has a complex pharmacokinetic profile with extremely large interpatient variability and many well-documented drug-drug interactions, which presents special challenges in dose optimization and requires vigilant clinical monitoring for cardiovascular, neurologic, and hematologic adverse effects. Expand
...
1
2
3
4
5
...